CTOs on the Move

Registrat

www.registrat.com

 
Registrat, Inc. is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.registrat.com
  • 2343 Alexandria Dr Ste 400
    Lexington, KY USA 40504
  • Phone: 859.223.4334

Executives

Name Title Contact Details

Similar Companies

Industrial Facilities Design Inc

Industrial Facilities Design Inc is a Hopkinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chemrx

Chemrx is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orthobrain

At orthobrain®, we have reinvented the delivery of orthodontics, providing access to more people and providing dentists the opportunity to offer excellent orthodontic care to their patients. orthobrain`s consulting and education platform, powered by the expertise of Orthodontists, makes it faster, better, and easier than ever for general practitioners to deliver orthodontic care with confidence. With our system, your patients will obtain an Orthodontist-designed diagnosis, a step-by-step detailed treatment plan, and custom-made appliances from a trained dentist they already know and love - you! orthobrain makes it easy for you to start offering orthodontics in your practice immediately and transform your patients smiles for good.

Qosina

Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.